EQS-News: The Supervisory Board of Sartorius AG proposes a dividend of 0.74 euros per preference share

Göttingen, February 7, 2025

The Supervisory Board of Sartorius AG proposes
a dividend of 0.74 euros per preference share

The Supervisory Board of Sartorius AG resolved at its meeting today to approve the recommendation of the Executive Board to submit a proposal to the Annual General Meeting on March 27, 2025, to pay a dividend of 0.74 euros per preference share and 0.73 euros per ordinary share for fiscal 2024, the same amount as for the previous year. Under this proposal, the total distributed profit would be 50.7 million euros. The dividend will be paid on April 1, 2025.

This press release contains forward-looking statements about the future development of the Sartorius Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius assumes no liability for updating such statements in light of new information or future events.
Financial calendar
February 17, 2025            Publication of Annual Report
March 27, 2025                  Annual Shareholders’ Meeting
April 16, 2025                     Publication of the first quarter results January to March 2025
July 22, 2025                       Publication of the half-year results January to June 2025
October 16, 2025             Publication of the nine-month results January to September 2025
A profile of Sartorius
Sartorius is a leading international partner of life sciences research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions Division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies safely, rapidly, and sustainably. The company, based in Göttingen, Germany, has a strong global reach with around 60 production and sales sites worldwide. Sartorius regularly expands its portfolio through the acquisition of complementary technologies. In 2024, the company generated sales revenue of around 3.4 billion euros. Around 13,500 employees are working for customers around the globe.

Visit our Newsroom and follow Sartorius on LinkedIn.

Contact
Leona Malorny
Head of External Communications
+49 551 308 4067
leona.malorny@sartorius.com